Estée Lauder unveils its new skin longevity initiative, which is the next frontier in beauty

-Estée Lauder today unveiled its new Skin Longevity platform, which is based on 15 years of expertise in pioneering research into skin longevity. With new product innovation based on cutting-edge anti-aging technology, Estée Lauder is pioneering a new frontier in…

Read MoreEstée Lauder unveils its new skin longevity initiative, which is the next frontier in beauty

Atomic AI Creates First Large Language Model Using Chemical Mapping Data to Optimize RNA Therapeutic Development

Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, announced that the Company has created the first large language model (LLM) leveraging chemical mapping data. In a preprint paper published on…

Read MoreAtomic AI Creates First Large Language Model Using Chemical Mapping Data to Optimize RNA Therapeutic Development

Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

 announced today that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell…

Read MoreVertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Parse Biosciences Closes $50 Million in Financing to Promote Continued Global Growth

Finanzierung wird Erweiterung des Produktportfolios des Unternehmens vorantreiben und kommerzielle Reichweite erweitern  ein führender Anbieter von leicht zugänglichen und skalierbaren Lösungen für die Einzelzellsequenzierung, gab heute bekannt, dass das Unternehmen Kapital in Höhe von 50 Millionen US-Dollar durch eine Serie-C-Finanzierungsrunde…

Read MoreParse Biosciences Closes $50 Million in Financing to Promote Continued Global Growth

IPA Announces Closing of $1.265 Million Public Offering of Common Shares

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced the closing of its $1.265 million underwritten public offering of 1,265,000 common shares, including 165,000 common shares issued pursuant to the full exercise by the underwriter of…

Read MoreIPA Announces Closing of $1.265 Million Public Offering of Common Shares

RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation

RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a 20-patient pilot clinical trial to examine the safety and efficacy of the company’s bone adhesive biomaterial called TETRANITE® to immediately stabilize and fixate…

Read MoreRevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation
Sensei

bluebird bio Announces FDA Approval of LYFGENIA for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or “bluebird”) today announced the U.S. Food and Drug Administration (FDA) has approved LYFGENIA™ (pronounced as ‘lif-JEN-ee-uh’) (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12…

Read Morebluebird bio Announces FDA Approval of LYFGENIA for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events